Companies · Biotechnology

Jivana Biotechnology Inc

Oak Park · Biotechnology

Diligence memoA one-page analyst read on Jivana Biotechnology Inc — recommendation, valuation, rhythm, risks.
$2.0M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 73%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Oct 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Jivana Biotechnology Inc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.61× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 9.7 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Jivana Biotechnology Inc is one of 4293 Biotechnology companies tracked from Oak Park. By capital raised it ranks in the long tail (ahead of 28% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 504
Reg D exemption
2013
Year incorporated
2016-10-10
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2015-07-01 Raised $750K (real) Modeled valuation $41M (est)$750K$41MPre-Seed2015Pre-Seed · 2015-12-01 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2015Pre-Seed · 2016-07-01 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2016Pre-Seed · 2016-07-01 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2016Pre-Seed · 2016-10-10 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2016+$1.0M+$1.0M+$1.0M+$1.0MCumulative $4.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$750K · 2015
Pre-Seed extension$1.0M · 2015
Pre-Seed extension$1.0M · 2016
Pre-Seed extension$1.0M · 2016
Pre-Seed extension$1.0M · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$55.2M
Base estimate est.
$533K
Conservative case
$626.0M
Upside case
$5.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $41.4M · 2015-07-012015Pre-Seed · modeled $55.2M · 2015-12-01Pre-Seed · modeled $55.2M · 2016-07-01Pre-Seed · modeled $55.2M · 2016-07-01Pre-Seed · modeled $55.2M · 2016-10-102016
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
9.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$1.6M/yr
Capital velocity
11.0 yr
On record since
2015
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.0M
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 2.4× above median
This company$1.0M
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.9× of median
This company$55.2M
Sector median$64.2M

Raised more than 28% of sector peers (real $). Modeled value above 48% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 152.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)New Vital Signs, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Cerebral Magnetics INC · Pre-Seed Raised $1.0M · modeled $55.2M (est)NutriBand Inc. · Pre-Seed Raised $1.2M · modeled $55.2M (est)AnTolRx, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)US Biologic, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Zeta Biolongevity, Inc. · Pre-Seed Raised $995K · modeled $54.9M (est)ALRGN Bio, Inc. · Pre-Seed Raised $946K · modeled $52.2M (est)Cellsolutions Llc · Pre-Seed Raised $1.9M · modeled $49.7M (est)BioSurfaces, LLC · Pre-Seed Raised $900K · modeled $49.7M (est)Pique Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $47.2M (est)Gradient Pharmaceuticals, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)Jivana Biotechnology Inc (this company) Raised $2.0M · modeled $55.2M (est)Jivana Biotechnology Inc
CompanyStageRaised · realValue · estvs peer med.
New Vital Signs, Inc.Pre-Seed$1.0M$55.2M2.61×
Cerebral Magnetics INCPre-Seed$1.0M$55.2M2.61×
NutriBand Inc.Pre-Seed$1.2M$55.2M2.61×
Jivana Biotechnology Inc this companyPre-Seed$2.0M$55.2M2.61×
AnTolRx, Inc.Pre-Seed$1.0M$55.2M2.61×
US Biologic, Inc.Pre-Seed$1.0M$55.2M2.61×
Zeta Biolongevity, Inc.Pre-Seed$995K$54.9M2.60×
ALRGN Bio, Inc.Pre-Seed$946K$52.2M2.47×
Cellsolutions LlcPre-Seed$1.9M$49.7M2.35×
BioSurfaces, LLCPre-Seed$900K$49.7M2.35×
Pique Therapeutics, Inc.Pre-Seed$1.4M$47.2M2.23×
Gradient Pharmaceuticals, Inc.Pre-Seed$850K$46.9M2.22×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$750K2015-07-01$4.2M$41.4M85%
Pre-Seed$1.0M2015-12-01$5.6M$55.2M85%
Pre-Seed$1.0M2016-07-01$5.6M$55.2M85%
Pre-Seed$1.0M2016-07-01$5.6M$55.2M85%
Pre-Seed$1.0M2016-10-10$5.6M$55.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$750K2015-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$1.0M2015-12-01
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 16 investors on this round.
  3. Pre-Seed$1.0M2016-07-01
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Pre-Seed$1.0M2016-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  5. Pre-Seed$1.0M2016-10-10
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2017 ~Q1
Modeled next raise · ~4mo cadence
$1.0M
Modeled next size est.range $1.0M$1.6M
1.0×
Last step-up
$1.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kenneth Templin1 other2015-07
Sidney Hopps1 other2015-07
Registry & provenance

Jivana Biotechnology Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1659624
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Adze Biotechnology IncBiotechnologySeries A$9.8M$60.8Mnetwork2 shared operators · same sector
Advanced Bionutrition CorpBiotechnologyPre-Seed$2.1M$49.7Msame sector · same stage
Ntxbio, LlcBiotechnologyPre-Seed$1.9M$50.5Msame sector · same stage
Cellsolutions LlcBiotechnologyPre-Seed$1.9M$49.7Msame sector · same stage
KDx Diagnostics, Inc.BiotechnologyPre-Seed$1.7M$45.3Msame sector · same stage
INTICA Biomedical, Inc.BiotechnologyPre-Seed$1.6M$54.9Msame sector · same stage
Act Biotech IncBiotechnologyPre-Seed$2.5M$55.2Msame sector · same stage
Olive Medical CorpBiotechnologyPre-Seed$2.6M$55.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Neurvana Medical, LLCBiotechnologySeed$144.0M82%
Linus Biotechnology Inc.BiotechnologySeries B$42.5M80%
Jiufuyuan Biotechnology Co., LtdManufacturingSeries A$47.0M80%
Jitai Biological Technology LtdBiotech / PharmaSeries A$11.7M79%
Carcinotech Ltd.BiotechnologyPre-Seed$3.3M78%
Kezar Life Sciences, Inc.BiotechnologySeries C$2.0B78%
Kovina Therapeutics Inc.BiotechnologySeed$51.3M78%
BioVaxys Technology Corp.BiotechnologyPre-Seed$7.2M78%
Frequently asked
How much funding has Jivana Biotechnology Inc raised?
Jivana Biotechnology Inc has raised approximately $2.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Jivana Biotechnology Inc's estimated valuation?
Provath's modeled valuation for Jivana Biotechnology Inc is approximately $55.2M (modeled range $533K–$626.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Jivana Biotechnology Inc at?
Jivana Biotechnology Inc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Oct 10.
What does Jivana Biotechnology Inc do and where is it based?
Jivana Biotechnology Inc operates in the Biotechnology sector, based in Oak Park.
Explore related

See where Jivana Biotechnology Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Jivana Biotechnology Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.